12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Levomilnacipran regulatory update

Forest submitted an NDA to FDA for levomilnacipran to treat major depressive disorder (MDD) in adults. Forest has...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >